The Icahn School of Medicine in Mount Sinai, New York, has launched a regenerative medicine laboratory to advance research into new pathways to treat diseases ranging from leukemia to Alzheimer’s, breast cancer and airway diseases.
According to Dennis S. Charney, the institute advances and coordinates research and training in a wide range of areas of regenerative biology and medicine across Mount Sinai’s basic sciences and clinical departments, each dedicated to a subset of diseases and disorders. It is planned to cover three centers focused on , MD, Anne and Joel Ehrenkranz Icahn Dean of Mount Sinai and President of Academic Affairs for Mount Sinai Health System.
The Institute includes the Alper Center for Neurodevelopment and Regeneration, the Center for Epithelial and Airway Biology and Regeneration, and the Center for Advances in Hematologic Cancer Treatment.
“The Regenerative Medicine Institute is dedicated to transforming how we treat regenerative diseases that affect millions of lives,” said Charney. “Clinicians, scientists, and researchers across Mount Sinai will continue to leverage their expertise and discoveries in human biology and regenerative medicine to rapidly translate our findings to help address the most challenging disorders affecting patients. It will improve care and treatment for several of certain developmental and degenerative conditions.”
Alper Neurodevelopment and Regeneration Center
Researchers, scientists, and clinicians at the Alper Center for Neurodevelopment and Regeneration, co-funded by the Friedman Brain Institute, focus on the brain, its development, and its role in disease. Scientists are using research techniques such as cell cultures, animal models, and human tissue studies to seek new insights into how the nervous system works and to identify new ways to prevent and treat brain disorders.
“The future of regenerative medicine for brain disorders lies in understanding how the brain develops and is maintained throughout life,” said the center’s director and associate professor of neuroscience at Icahn Mount Sinai. Dr. Nan Yang said. “Our goal is to advance research on models of human disease and develop novel therapeutics that can lead to the cure or alleviation of conditions such as neurodevelopmental disorders and neurodegeneration such as autism, epilepsy, Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, etc. It’s about identifying prevention and treatment strategies.”
Center for Epithelial and Airway Biology and Regeneration
The Center for Epithelial and Airway Biology and Regeneration, co-hosted by the Institute of Airway Science, promotes collaboration among scientists treating diseases of epithelial tissues such as the skin, lungs, trachea, oral cavity, breast, liver, stomach, and intestines. increase. ,esophagus. These conditions include sinus disorders, lung injuries, tracheal and lung transplants, breast cancer, severe asthma, eczema, psoriasis, and hair loss. Scientists conduct research related to epithelial development, stem cells, regeneration, and disease.
The Center also provides pilot grants for innovative and collaborative research projects, collaborating with basic, translational and clinical researchers to advance research results for clinical application. provide a formal basis for
“The Center for Epithelial and Airway Biology and Regeneration defines translational research. We will provide a platform for” Sinai Health System and Icahn Mount Sinai. The scientific directors of the center are Dr. Ya-Wen Chen, Assistant Professor of Otolaryngology and Cell, Developmental and Regenerative Biology, and Dr. Elena Ezhkova, Professor of Cell, Developmental and Regenerative Biology and Dermatology.
Hematologic Cancer Treatment Promotion Center
The Center for Advancement of Blood Cancer Therapies, co-sponsored by the Tissue Cancer Institute, is dedicated to the research and development of new therapies, including conventional drugs and cell therapies, in pediatric and adult blood cancers . Of particular focus are human models of hematopoiesis and leukemia based on induced pluripotent stem cells and primary blood cells, combining gene editing and single-cell technology.
“This new center will bring together researchers with a commitment to hematological research with the direct aim of elucidating the mechanisms and developing new treatments for human hematological disorders such as adult and pediatric leukemia and myelodysplastic syndromes. Center for Advances in Hematologic Cancer Therapy and Professor of Oncology at the Tissue Cancer Institute: “Our researchers have made recent breakthroughs that have transformed the ability to experiment with human cells.” and the Center fosters close relationships between researchers and clinicians.”
Regenerative medicine laboratories also include the Black Family Stem Cell Institute, established in 2005 on Mount Sinai to integrate research in embryonic stem cell and adult stem cell biology. We will continue to advance research in stem cell biology to accelerate translation to improve patient care in the clinical setting, including the development of new drugs and cell-based therapeutics tested for safety and efficacy.
Dr. Sarah E. Millar, who leads the Black Family Stem Cell Institute, will serve as director of the Institute for Regenerative Medicine.